Zobrazeno 1 - 10
of 308
pro vyhledávání: '"Tsutomu, Kagiya"'
Autor:
Dhanya K. Chandrasekharan, Tsutomu Kagiya, Pawan K. Khanna, Cherupally Krishnan Krishnan Nair
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 26:249-257
Silver nanoparticles were prepared from silver nitrate using a vitamin C derivative, 6-palmitoyl ascorbic acid-2-glucoside (PAsAG), via a sonochemical experiment. The resultant golden yellow solution that contained silver nanoparticle-PAsAG complex (
Publikováno v:
Journal of Radiation Research. 50:203-212
A palmitoyl derivative of ascorbic acid 2-glucoside, 6-palmitoyl ascorbic acid-2-glucoside (PAsAG), which possess good antioxidant properties, is examined for radioprotection in vitro, ex vivo and in vivo models. PAsAG protected plasmid DNA from gamm
Autor:
Cherupally Krishnan Krishnan Nair, Jasmin A. Jacob, Tulsi Mukherjee, Tsutomu Kagiya, Dani Mathew, Nandita Biswas, Sudhir Kapoor
Publikováno v:
Journal of Radiation Research. 48:369-376
Ascorbic acid monoglucoside (AsAG), a glucoside derivative of ascorbic acid, has been examined for its antioxidant and radioprotective abilities. AsAG neutralized 1, 1 diphenyl -2-picryl-hydrazyl (DPPH), a stable free radical in a concentration depen
Autor:
Hideo Tatsuzaki, V. Tsutomu Kagiya, Nagraj G. Huigol, Noor-I-Alam Kizilbash, Ranapala S. Jayatilake, Sait Okkan, W. Dobrowsky
Publikováno v:
Radiotherapy and Oncology. 82:24-29
Purpose AK-2123, a nitrotriazole hypoxic cell sensitizer, has reportedly improved results in head and neck cancers, uterine cervical cancers and other solid tumours when added to radical radiotherapy. A prospectively randomised trial was initiated by
Autor:
Dobrowsky, Werner, G., Huigol Nagraj, S., Jayatilake Ranapala, Kizilbash, Noor-l-Alam, Okkan, Sait, Tsutomu, Kagiya V., Tatsuzaki, Hideo, et.al
Publikováno v:
Radiotherapy and Oncology. 82(1):24-29
PURPOSE: AK-2123, a nitrotriazole hypoxic cell sensitizer, has reportedly improved results in head and neck cancers, uterine cervical cancers and other solid tumours when added to radical radiotherapy. A prospectively randomised trial was initiated b
Autor:
Anna Shishkina, Hironobu Murase, Tsutomu Kagiya, Ivan Butorin, Polina Gervas, Nadezda Cherdyntseva
Publikováno v:
Journal of Radiation Research. 46:37-41
A preparation of alpha-tocopherol monoglucoside (TMG) administered i.p. at a dose of 600 mg/kg immediately after whole body gamma irradiation was examined for its radioprotective efficacy towards bone marrow and peripheral blood nucleated cells. When
Publikováno v:
Journal of Radiation Research. 44:359-365
Sanazole/AK-2123/γ-Radiation/DNA damage/Apoptosis/Radiosensitizer. Sanazole (AK-2123) (N-2′-methoxy ethyl)-2-(3″-nitro-1″-triazolyl)acetamide, which has completed phase III clinical trials as a radiosensitizer, enhanced γ-radiation induced ap
Autor:
Cherupally Krishnan Krishnan Nair, Anna A Ivanova, Nadezda Cherdyntseva, Evgeny Cherdyntsev, Tsutomu Kagiya, Vladimir V Ivanov
Publikováno v:
Journal of Cancer Research and Therapeutics, Vol 9, Iss 3, Pp 364-369 (2013)
Aim: To investigate the potential of the anti-oxidant ascorbic acid glucoside (AA-2G) to modulate neurotoxicity induced by high doses of nitrotriazole radiosensitizer. Materials and Methods: Male and female C56Bl/6xCBA hybrid mice aged 8-14 weeks (we
Autor:
Hideya, Yamazaki, Satoaki, Nakamura, Takuya, Nishimura, Naohiro, Kodani, Takuji, Tsubokura, Takuya, Kimoto, Hiroya, Sihomi, Norihiro, Aibe, Ken, Yoshida, Masahiko, Koizumi, Tsutomu, Kagiya
Publikováno v:
Anticancer research. 33(4)
Reirradiation is a challenging field in the treatment of recurrent brain metastases. Because of the elevated risk of radiation toxicity due to previous irradiation, only a limited dose is prescribed. To enhance radiosensitivity, in the present analys
Autor:
Hideya, Yamazaki, Satoaki, Nakamura, Takuya, Nishimura, Haruumi, Okabe, Norihiro, Aibe, Ken, Yoshida, Tsutomu, Kagiya
Publikováno v:
Anticancer research. 33(4)
Glioblastoma has a very poor prognosis even after incorporation into therapy of the newly-developed drug, temozolomide.We present a case of 62-year-old woman with glioblastoma multiforme treated with tomotherapy intensity-modulated radiation therapy